LAST WEEK TODAY!

A summary of what was published on ProstateWarriors.com during the past week

Hi fellow warriors! In this week’s update, we’re sharing fresh developments, powerful ideas, and a dose of inspiration to keep us moving forward together. Stay strong and fight on!

As usual, we also have a podcast if you prefer to listen to the newsletter, you can find it HERE.​

Clinical Research

• Enzalutamide Improves PSA Control in High-Risk Recurrent Prostate Cancer​
  A post hoc analysis from the Phase 3 EMBARK trial showed that enzalutamide, both with leuprolide and as monotherapy, significantly improved PSA control in patients with high-risk biochemically recurrent prostate cancer(PSA doubling time ≤9 months).
  By week 25, undetectable PSA levels were achieved in 89% of patients on the combination, 82% on enzalutamide alone, and 63% on leuprolide alone. Upon retreatment after PSA relapse, undetectable levels were restored in 96%, 90%, and 73% of patients, respectively. These responses were linked to improved metastasis-free survival, suggesting durable disease control.
  ​
• Phase I Trial Launches for New Imaging and Therapeutic Agents (AZD2284, AZD2287, AZD2275)​
  A first-in-human trial is evaluating the safety and early efficacy of three investigational agents in patients with mCRPC.Part A focuses on imaging: determining the optimal dose of AZD2287 and assessing PSMA and STEAP2 biomarker expression. Pre-treatment with AZD2275 may enhance uptake. Part B transitions to therapy, using Actinium-225–conjugated AZD2284to target cancer cells. The study is exploratory but aims to optimize personalized targeting strategies in prostate cancer.
  ​
• AI-Designed Drug Pocenbrodib Begins Phase 1/2 Trial in mCRPC​
  Pocenbrodib (formerly CTT2274), developed with artificial intelligence, has entered clinical testing for mCRPC. It targets the p300/CBP epigenetic regulators that support cancer cell survival. The trial will assess safety, tolerability, and preliminary efficacy, as well as how effectively the drug engages its target. Notably, pocenbrodib advanced from concept to clinical trial in under 30 months—significantly faster than traditional development timelines—underscoring the promise of AI in oncology drug design.
  ​
• LIBERTAS Trial Evaluates De-escalation in Responsive mHSPC Patients​
  The Phase III LIBERTAS trial investigates whether reducing therapy intensity in mHSPC patients who respond to initial treatment can preserve outcomes while minimizing side effects. Patients with undetectable PSA after six months of ADT plus apalutamide are randomized to either continue full therapy or receive apalutamide alone with intermittent ADT. The trial seeks to determine if less intensive treatment can maintain disease controlwhile reducing common burdens such as fatigue, hot flashes, and sexual dysfunction. Early data shows a 71% undetectable PSA rate after six months; efficacy outcomes are pending.

Preclinical Research

• MTX-531: A Dual-Target Strategy Against Resistance​
  MTX-531 is a novel agent designed to overcome resistance in prostate cancer by simultaneously targeting EGFR and PI3K pathways—both implicated in tumor survival and progression. Though EGFR is less studied in prostate cancer, its activation has been associated with aggressive disease. Preclinical studies in other solid tumors have shown strong anti-tumor effects, supporting further investigation in resistant prostate cancer models.
  ​
• Telomir-1 Combats Cancer and Reduces Chemotherapy Toxicity​
  Telomir-1, a small molecule, shows promise in both suppressing tumor growth and protecting against chemotherapy-induced side effects.
  ​It works by regulating copper and iron metabolism, reducing oxidative stress, and activating telomerase to promote genomic stability. In preclinical prostate cancer models, Telomir-1 reduced tumor burden by 50%. When combined with paclitaxel, it improved survival and reduced toxicity in treated animals.
  ​
• Trop-2 Identified as a High-Priority Therapeutic Target​
  Trop-2, a surface antigen overexpressed in many cancers, including mCRPC, is linked to poor prognosis and resistance, especially in tumors expressing AR-V7. Antibody-drug conjugates (ADCs) like sacituzumab govitecan, already approved in other cancers, are being tested in prostate cancer. Early studies suggest efficacy correlates with Trop-2 expression. Trop-2 also shows potential as a biomarker for treatment selection and disease monitoring. Combining Trop-2–targeted ADCs with PARP inhibitors or immunotherapies may enhance outcomes in advanced disease.

And…that’s all folks! For today at least!
Please let me know if there is anything I can improve in my newsletters, and let me know if you have enjoyed the podcast.

If you this newsletter was delivered to your SPAM folder, make sure to let your email system know that it is not spam.
​
​
Have a great weekend!

Max